Full Press Release Details
ISORAY, INC. REPORTS THIRD QUARTER RESULTS
Institutional Interest On The Rise Following
Recently Published Reports
Cesium-131's Success in Treating Cancer
RICHLAND, Washington (May 18, 2015) - IsoRay, Inc. (NYSE
MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment
of prostate, brain, lung, head and neck and gynecological cancers, announced its financial results for the quarter and nine months
ended March 31, 2015. Recent publications are having a positive impact in the marketplace with new institutions seeking licenses
to offer Cesium-131 treatment. While revenue increased a nominal two percent between the quarter ended March 31, 2014 and the quarter
ended March 31, 2015, revenue was basically flat when comparing the nine month periods. IsoRay has a current cash balance of over
$20,000,000 with no debt.
IsoRay's management continues to diversify its product
offerings. Several new institutional based studies are in the final stages of implementation and their launch should be announced
shortly. These studies involve new body sites or are designed to test new theories on how to better treat cancer patients with
the hope of lessening patient side effects thus providing improved quality of life. Many of the Cesium-131 cases currently being
performed outside the prostate are performed on patients that have aggressive cancers which to date have failed current standard
of care options. Management continues to believe the prostate market has bottomed out at this time. Management continues to see
slow adoption for IsoRay's international sales efforts, with the devaluation of the Euro causing its products to become higher
IsoRay has been very active in marketing its product line at
numerous new venues in support of the growing number of body sites currently treated with Cesium-131. IsoRay exhibited at a number
of national conventions and regional conferences and also sponsored industry leaders in formal dinner presentations noting the
methods and successes of using Cesium-131 to treat specific cancer types. National meetings attended include the American Association
of Neurological Surgeons, Society of Gynecological Oncology and The Society of Thoracic Surgeons. Isoray supported several institutional
sponsored events including Rutgers (Robert Wood Johnson)-Cancer Institute of NJ 2015 4-R Symposium and Weill Cornell Advances in
Brachytherapy, An International Symposium.
IsoRay Chairman and CEO Dwight Babcock commented, "Clinical
evidence provided through protocols/studies performed by major medical centers is proving utilizing Cesium-131 is either equal
to or better than the current standard of care alternatives. This evidence, coupled with patients enjoying an improved quality
of life, remains the key to IsoRay's success. Studies also aid in generating awareness and ultimately general adoption by
community hospitals and physicians, which will in turn drive consumers to our product offerings. To this end and given this growing
acceptance and interest in our now published results, IsoRay remains committed to our strategic sales and marketing objectives,
which we believe will contribute to long term growth and achieving profitability."
IsoRay, Inc. and Subsidiaries
Consolidated Statements of Operations
| For the three | For the nine | |||||||||||||||
| months ended | months ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Product sales, net | $ | 1,158,109 | $ | 1,134,319 | $ | 3,265,795 | $ | 3,269,642 | ||||||||
| Cost of product sales | 1,102,912 | 1,083,413 | 3,303,364 | 3,329,950 | ||||||||||||
| Gross profit / ( loss) | 55,197 | 50,906 | (37,569 | ) | (60,308 | ) | ||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development expenses | 141,399 | 153,611 | 458,636 | 470,631 | ||||||||||||
| Sales and marketing expenses | 374,876 | 245,558 | 1,032,402 | 931,210 | ||||||||||||
| General and administrative expenses | 589,934 | 640,732 | 1,703,825 | 1,805,732 | ||||||||||||
| Total operating expenses | 1,106,209 | 1,039,901 | 3,194,863 | 3,207,573 | ||||||||||||
| Operating loss | (1,051,012 | ) | (988,995 | ) | (3,232,432 | ) | (3,267,881 | ) | ||||||||
| Non-operating income (expense): | ||||||||||||||||
| Interest income | 68,954 | 556 | 214,009 | 1,391 | ||||||||||||
| Change in fair value of warrant derivative liability | 28,605 | (1,095,000 | ) | 375,605 | (1,014,000 | ) | ||||||||||
| Finance and interest expense | (100 | ) | - | (3,551 | ) | (827 | ) | |||||||||
| Non-operating income (expense), net | 97,459 | (1,094,444 | ) | 586,063 | (1,013,436 | ) | ||||||||||
| Net loss | (953,553 | ) | (2,083,439 | ) | (2,646,369 | ) | (4,281,317 | ) | ||||||||
| Preferred stock deemed dividends (Note 10) | - | - | - | (726,378 | ) | |||||||||||
| Preferred stock dividends | (2,658 | ) | (2,658 | ) | (7,974 | ) | (7,974 | ) | ||||||||
| Net loss applicable to common shareholders | $ | (956,211 | ) | $ | (2,086,097 | ) | $ | (2,654,343 | ) | $ | (5,015,669 | ) | ||||
| Basic and diluted loss per share | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.13 | ) | ||||
| Weighted average shares used in computing net loss per share: | ||||||||||||||||
| Basic and diluted | 54,883,551 | 42,506,077 | 54,878,297 | 38,852,980 |
The accompanying notes are an
integral part of these financial statements
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is
the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body. Learn more about
this innovative Richland, Washington company and explore the many benefits and uses of GliaSite and Cesium-131 by visiting
Safe Harbor Statement
Statements in this news release about IsoRay's future
expectations, including: the advantages of our products and their delivery systems, future demand for IsoRay's existing and
planned products, whether revenue and other financial metrics will improve in future periods, whether IsoRay will be able to continue
to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether
the use of our products will increase or continue, whether additional medical centers will obtain licensure to offer our products
or will begin using our products, whether new studies will be launched, whether additional studies will be published or presented
with favorable outcomes from treatment with our products, whether we will continue to receive support from industry leaders, whether
awareness of our products in the medical community will continue or increase, whether our sales and marketing efforts will be successful,
and all other statements in this release, other than historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express
purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors
as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and
proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, patient results achieved
using our products in both the short and long term, success of future research and development activities, patient results achieved
when our products are used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to
successfully manufacture, market and sell its products, IsoRay's ability to manufacture its products in sufficient quantities
to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and
marketing efforts, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes
in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions
of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions
of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain
all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance
with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.